Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Open Label, Safety And Preliminary Efficacy Study of MRx0518 In Combination With Pembrolizumab In Patients With Advanced Malignancies Who Have Progressed On PD-1/PD-L1 Inhibitors

NCT03637803 is registered in ClinicalTrials.gov with 4D pharma plc as lead sponsor.

NCT NCT03637803
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03637803 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Open Label, Safety And Preliminary Efficacy Study of MRx0518 In Combination With Pembrolizumab In Patients With Advanced Malignancies Who Have Progressed On PD-1/PD-L1 Inhibitors
Lead sponsor
4D pharma plc
Phase
Phase 1/2
Overall status
Terminated
Start date
January 10, 2019
Completion date
May 8, 2023
Enrollment
63 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

bladder cancer, melanoma, non small cell lung cancer, oncology, renal cell carcinoma, solid tumor